Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.
Antonio Palumbo
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Millennium; Onyx
Francesca Gay
Consultant or Advisory Role - Byotest; Celgene
Honoraria - Celgene; Janssen
Pellegrino Musto
Honoraria - Celgene; Janssen
Tommaso Caravita
Honoraria - Janssen
Research Funding - Celgene
Alessandra Larocca
Honoraria - Celgene; Janssen
Davide Rossi
No relevant relationships to disclose
Dina Ben Yehuda
No relevant relationships to disclose
Massimo Offidani
No relevant relationships to disclose
Francesca Donato
No relevant relationships to disclose
Paola Finsinger
No relevant relationships to disclose
Paola Omedè
No relevant relationships to disclose
Concetta Conticello
No relevant relationships to disclose
Arnon Nagler
No relevant relationships to disclose
Roberto Ria
Consultant or Advisory Role - Celgene; Italfarmaco; Janssen; Novartis
Maide Cavalli
No relevant relationships to disclose
Roberto Mina
No relevant relationships to disclose
Maria Teresa Petrucci
No relevant relationships to disclose
Izhar Hardan
No relevant relationships to disclose
Federica Cavallo
Consultant or Advisory Role - Celgene
Honoraria - Celgene; Janssen; Onyx
Mario Boccadoro
Consultant or Advisory Role - Celgene; Janssen
Research Funding - Celgene; Janssen